October 13, 2026 — scheduled focused research update

Home · Latest · Milestones

Focused review of 32 active condition topics in six groups. The retained Sleep hub provides inherited history, not another monitoring assignment. Searches overlap seven days before the last full successful check; unfinished Sleep baselines also require preceding ninety-day context. Source dates remain separate from this review date. Worldwide/full-topic coverage remains incomplete and successful-check dates are preserved.

Findings

• 2026-10-13 — Trial-registry update: Forazapadin registers a placebo-controlled muscle-force trial in FSHD.
• 2026-10-13 — Trial-registry update: Abaloparatide–denosumab study records primary completion, with results still absent.
• 2026-09-17 — Trial-registry update: C-CAR168 plans a dual-target CAR-T trial for progressive multiple sclerosis.
• 2026-10-13 — Trial-registry update: SUPRA-COPD will test urolithin A alongside pulmonary rehabilitation.
• 2026-10-13 — Trial-registry update: Inhaled cell therapy registers an early COPD safety study.
• 2026-10-13 — Trial-registry update: Large shingles-vaccine trial will measure cardiovascular events.
• 2026-10-12 — Peer-reviewed randomized human challenge study: Travelan’s full challenge-study report retains a nonsignificant primary result.
• 2025-03-21 — Historical baseline; Trial-registry update: Baseline recovery: TNP-2092 tests local antibiotic treatment for prosthetic-joint infection.
• 2026-09-29 — Peer-reviewed randomized Phase 2 primary abstract; full supplement unreviewed: ZUPREME-1 publication adds exact doses, uncertainty and gastrointestinal event counts.
• 2026-10-13 — New Phase 3 human-trial registration; not yet recruiting: MariTide registers a home-autoinjector study.
• 2026-09-25 — Historical baseline; Recovered Phase 3 registry and sponsor protocol baseline; no results: SELENE-3 studies lenbelintide added to an established incretin regimen.
• 2026-10-09 — Unconfirmed informal safety signal; original Reddit comment: Anonymous ENLIGHTEN-6 report describes sleep disruption and skin sensitivity.
• 2026-10-13 — Newly public Phase2 human-study registration; completed earlier, no posted results: ELITE adds a retrospectively registered healthy-aging combination trial.
• 2026-10-13 — Primary trial-registry timing revision; no new lipid or outcome result: ARO-DIMERPA’s primary-completion estimate moves to July 2027.
• 2026-07-14 — Historical baseline; Recovered Phase 3 registry and sponsor protocol baseline; no results: NEBULA-1 tests clinical liver outcomes in compensated MASH cirrhosis.
• 2026-10-13 — New human device-study registration; retrospective, no posted results: A breathing-linked sound application registers a sham-controlled laboratory study.
• 2026-10-12 — Dated sponsor conference-program announcement; no new quantitative readout: AD109 schedules new CHEST analyses beyond the apnea index.
• 2026-06-09 — Historical baseline; Recovered Phase2 randomized crossover protocol baseline; no results: DReAMzz tests an alternative oral apnea combination.
• 2026-10-13 — New Phase1/2 human-trial registration; earlier actual start, noresults: Ofatumumab enters a small uncontrolled narcolepsy-type1 trial.
• 2026-10-09 — Historical baseline; Registry status reconciliation; noresults: Delayed-phase tasimelteon trial now reports actual completion.
• 2026-10-13 — New nonrandomized feasibility-study registration; noresults: A new ICU protocol measures circadian hormones and sleep architecture.
• 2025-09-17 — Historical baseline; Recovered human basic-science protocol; noresults: A separate spinal-cord-stimulation study investigates RLS physiology.
• 2026-10-13 — New formal human device-study registration; no results: SOARA plans to measure ovarian-screening harms and diagnostic burden.
• 2026-10-13 — New registration of an ongoing prospective case-control study; no results: A urine lung-cancer test enters prospective validation in never-smokers.
• 2026-10-05 — Peer-reviewed randomized diagnostic-disclosure trial; full primary article appraised: PLASMAR finds earlier blood-test disclosure changes memory-clinic decisions.
• 2026-10-12 — Peer-reviewed cross-sectional human study; primary abstract appraised, full tables/supplement inaccessible: AHEAD screening analysis finds differences in p-tau217 distributions.
• 2026-10-09 — New registration of an ongoing early device study; no outcomes posted: NMS-01 registers an early focused-ultrasound Alzheimer safety study.
• 2026-10-05 — Official regulatory request for information; not approval or efficacy evidence: FDA seeks input on the design and safety of ibogaine trials.
• 2026-10-13 — New formal phase 1/2a trial registration; explicitly not yet authorized to begin: IBO-CARE proposes an ibogaine comparison, pending funding and authorization.
• 2026-09-28 — Historical baseline; Recovered historical registry milestone; no efficacy readout: Recovered APPROACH registry confirms primary follow-up has ended.
• 2026-10-12 — Speculation/inference — unconfirmed; anonymous original Reddit post available only through indexing: Speculation: COMP360 could receive a decision 44–81 days after final submission.
• 2026-10-09 — New randomized human phase 2 registration; no efficacy results: PEACE registers an early post-trauma estradiol prevention pilot.
• 2026-10-01 — Sponsor commercial-launch announcement and Health Canada product record; no new comparative trial: BALANSYA adds a Canadian escitalopram liquid formulation.
• 2026-10-13 — New phase 3 randomized human trial registration; no result: T-bren registers a phase 3 study in HER2-expressing urothelial cancer.
• 2026-10-13 — New phase 2a human trial registration; no result: LUTEON ATLAS registers radiopharmaceutical dose optimization in kidney cancer.
• 2026-10-10 — Sponsor report of delivered AAO conference results; not a peer-reviewed full trial report: BRUNELLO adds visual-acuity intervals and a retinal safety imbalance.
• 2026-10-11 — Direct investigator interview and accompanying conference report; original slides/full follow-up dataset unappraised: MCO-010 four-year RP follow-up is now reported after AAO.
• 2026-10-12 — Peer-reviewed retrospective matched case-control study; full primary article appraised: Genotype-guided chemotherapy dosing is associated with less severe toxicity.
• 2026-10-04 — Peer-reviewed prospective newborn-screening implementation cohort; full primary article appraised: MLD newborn screening connects diagnosis to treatment and early development.
• 2026-10-05 — Peer-reviewed journal pre-proof; primary indexed abstract appraised, full article inaccessible: Newborn MECP2 findings highlight uncertain penetrance and family counseling.
• 2026-10-02 — Peer-reviewed long-term extension; full HTML appraised: Adult BRAVE-AA follow-up adds four-year response maintenance and five-year safety.
• 2026-09-16 — Sponsor announcement of planned human study; no in-patient hair efficacy: New-to-watch RLS-1496 hair-loss study remains a sponsor plan.
• 2026-10-13 — Newly registered randomized active-comparator human study; no results: HU-045 glabellar-line comparison enters the Phase3 registry.
• 2026-10-13 — Sponsor-posted randomized registry results; not peer-reviewed: Posted hyperpigmentation toner trial shows no clear added separation.
• 2026-10-07 — Peer-reviewed human-trial protocol plus original registry; no results: P11-4 protocol tests repeated application, with endpoint and timing discrepancies.

Coverage by topic

Whole-body MRI

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: whole body MRI screening HERCULES results October2026 September2026; whole body MRI October2026 screening outcomes; site:reddit.com whole body MRI October2026 clinical trial

Remaining gaps: Read current topic/state and shared notebook documents; searched September 5–October 13 overlap, including new publications and registry discovery. HERCULES live API remains recruiting in an April 2025 record, with no posted results; registry timing is unchanged old estimates.; New discovery matches were muscle imaging or diagnosed-disease assessment, not a qualifying repeated-screening outcome study. Reappraised saved October 1 JGIM review and October-issue Clinical Imaging commentary without duplicate event. SABI October 14 agenda includes general-public whole-body-MRI discussion, not an announced outcomes readout.; International registries, all downstream/repeated-round outcome literature and guidance changes remain incomplete.

Informal sources and unresolved claims: Targeted Reddit and podcast searches reviewed original/indexed material. October 11 Scholar request is for a 2021 paper, not fresh outcomes; Levels 313/Durand original October 1 transcript remains opinion about future adoption, not proven screening health benefit. No distinct attributable new development rumor selected; full podcast census incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6

Galleri and organ-specific cancer screening

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: October2026 Galleri FDA approval September23vote; October2026 cancer screening ovarian blood colorectal breast human trial; site:reddit.com Galleri October2026 approval

Remaining gaps: Read current Galleri/organ-specific page/state, September 5 overlap and all six named registries; no duplicate EDCC poster or prior nonbinding FDA-vote event. New SOARA and urine-VOC human-study registrations appraised with screening/diagnostic populations distinct.; New-study query returned 134 matches; first 100 screened, remaining page not retrieved. Broad query contains incidental cancer/screening terms. All organ-specific breast/colorectal/lung trials, FDA final-status/label database records and downstream-outcomes inventory remain incompletely refreshed.; October 8 BMJ Galleri opinion located as opinion, not a new trial result. No FDA approval inferred from its title, commercial access, press headlines or advisory vote. ESMO Oct 25/26 workup analyses remain scheduled.

Informal sources and unresolved claims: Targeted original/indexed Galleri informal searches did not yield a distinct new attributable trial/decision rumor. Misleading panel-approval headlines do not establish FDA marketing approval. Informal/podcast coverage incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11

GLP-1 and related metabolic therapies

Coverage: focused_incomplete. 4 newly recorded entries.

Searches: 2026-10-13: glp1 primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: glp1 original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 804 records across 9 pages; incidental studies excluded. Named topic records refreshed: 20. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.

Informal sources and unresolved claims: Opened original October 9 ENLIGHTEN-6 weekly thread and permalink, selecting clearly unconfirmed symptoms. October 11/12 discussion contains speculation about slower titration, future EloraTZP/retatrutide combinations and access dates; none is a sponsor commitment. SOLIS-1 original direct fetch failed again; official record now active-not-recruiting with 940 actual participants, but that does not validate the saved anonymous symptoms. Prior near-30% EloraTZP rumor remains unconfirmed; no new matching source recovered. Full original EASD/Q&A/audio still incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23
• Source 24
• Source 25
• Source 26
• Source 27
• Source 28
• Source 29
• Source 30
• Source 31
• Source 32
• Source 33
• Source 34
• Source 35
• Source 36
• Source 37

Muscle building and preservation

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: myostatin OR bimagrumab OR enobosarm OR muscle preservation OR deramiocel; trevogrumab COURAGE full publication; SAT-3247 current primary protocol; enobosarm Cantor original audio and trial-initiation follow-up; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 25 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved. COURAGE in-press full journal tables and BELIEVE withdrawal harms remain unrecovered; PPMD October7 original replay not appraised.

Informal sources and unresolved claims: Original October1 COURAGE Reddit repost and October7 program comment were revisited; neither is new confirmation. Enobosarm Cantor direction remains a third-party account; original audio and actual phase3 initiation unverified. Gray-market sourcing discussion excluded.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10

Longevity and healthspan trials

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-13: longevity primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: longevity original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 45 records across 1 pages; incidental studies excluded. Named topic records refreshed: 12. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; TAME direct page returned HTTP 404 again; indexed official AFAR still describes fundraising/planning, but its stale crawl is not a fresh launch check. No funded/actual start inferred. Disease-specific TRUTH MASH source retained once under liver. Full mTOR/senolytic original publications and safety review incomplete.

Informal sources and unresolved claims: Reopened actual Vitaei April 11 PEARL 24-month claim; same unrelated citation persists, so clinical follow-up remains unconfirmed with contradicted offered support, no new alert. Original secondary report claims not independent corroboration; targeted Reddit longevity searches did not yield a new source-verified development claim selected. Full audio incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17

Localized fat removal and cellulite

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: Named ClinicalTrials.gov API refresh and all pages of localized_fat discovery, LastUpdatePostDate September 5 to October 13, 2026; Primary sponsor/regulator/publisher and conference searches for localized_fat; October 9 to 13 prioritized, older within-window entries deduplicated; Original Reddit and selected podcast/transcript queries for localized_fat; unresolved earlier claims revisited; Europe PMC broad FirstPublicationDate September 5 to October 13 query; bounded title/abstract MED retry for hair, skin, scars, dental

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (90 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; SUPREME-01 remains recruiting 320 with July/September 2027 estimated completion and unchanged September 22 posting. SCULPT, CBL-0206, AYP-101, RZL-012 and tesamorelin named statuses/results remain as saved; no new China NDA acceptance, SUPREME-02 initiation or non-HIV tesamorelin indication verified. Caliway index still ends October 2; original EASD subgroup tables, broader cellulite comparative outcomes and rare-harm/regulator inventory remain gaps. Theratechnologies news page failed retrieval.

Informal sources and unresolved claims: October 10 HeliosClinical and October 12 gerosciencee CBL514 posts repeat the already saved EASD source; no independent confirmation. Recent tesamorelin self-experiment/sourcing posts excluded from formal-program efficacy; no new attributable trial timing signal selected. Full investor and podcast audio remains unreviewed.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21

Broad cardiovascular prevention, lipids and screening

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-13: cardiovascular primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: cardiovascular original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 514 records across 6 pages; incidental studies excluded. Named topic records refreshed: 19. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; ARO-DIMERPA revised completion was compared with saved October 9 raw August 18 record. Existing HEART-3, AMBIENCE, REFINE-CAC and lipid/outcome disclosures deduplicated. Root owns new zoster-vaccine MACE registration; cross-link infections once. No comprehensive international gene-editing, regulatory-label or long-term safety review completed.

Informal sources and unresolved claims: Targeted PCSK9/LDL Reddit and official-source searches; no distinct original development rumor selected. Original Curbsiders lipid-guidance notes retained without re-alert. Some exact-date searches returned irrelevant/old results; full podcast transcript/Q&A review remains incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23
• Source 24
• Source 25
• Source 26

Alzheimer's screening and therapies

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: October12 2026 Alzheimer clinical trial blood screening; Plasma Phosphorylated Tau217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease; Earlier Disclosure of Blood-Based Biomarkers Diagnostic Certainty Clinical Management; site:reddit.com Alzheimer October2026 trial

Remaining gaps: Read full active scope, prior gaps/state and September 5 overlap. Retrieved all 14 named registries and 35 new-registration matches. Appraised PLASMAR full randomized clinical-utility article and Oct 12 AHEAD primary abstract; NMS-01 device record separately appraised.; AHEAD full tables/supplement not available. All antibody labels/ARIA changes, blood-assay recalls, worldwide prevention cohorts and clinical-outcome inventory remain incomplete. Registry October 13 refreshes do not by themselves mean new efficacy or actual first dosing.

Informal sources and unresolved claims: Revisited Attia/Davidson public original source and SPINOZA live registry; cognitive-prevention hypothesis remains unconfirmed. October 10 Reddit semaglutide-prevention headline appears to repeat older observational associations and is not a new randomized benefit. Patient-care anecdotes and stock discussions not promoted. Full paid interview and broad podcast review remain incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21

Psilocybin and related therapies

Coverage: focused_incomplete. 4 newly recorded entries.

Searches: October2026 psilocybin clinical trial COMP360 MM120; site:fda.gov FDA Seeks Public Input to Support Ibogaine Research; FDA NDA and CNPV timelines to approval Compass Reddit; site:ir.compasspathways.com October2026 submission FDA

Remaining gaps: Read current topic, scope/state and September 5 overlap. Retrieved 11 saved registries and 12 new registrations; incidental LSD=procedure abbreviations excluded. Primary APPROACH actual-primary-completion access gap closed without efficacy claim; appraised FDA ibogaine RFI and conditional IBO-CARE plan.; Full FDA September hearing proceedings, all COMP/GH/Helus/Definium harms/durability tables, PMDD/new cancer-distress/BPD trial full appraisal and global registry census remain gaps. FDA consultation is not approval.

Informal sources and unresolved claims: Oct 12 original indexed CNPV timing calculation recorded explicitly as unconfirmed speculation; direct original access failed, author/full arithmetic unappraised. October 5 shroomstocks thread repeated registry-completion observations; only the actual registry date is now verified. MAPS original refiling statement revisited, no FDA acceptance independently verified. Full podcast/talk sweep incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20

Mental-health treatments, SSRIs and newer antidepressants

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: October2026 antidepressant clinical study trial results after:2026-10-09; BALANSYA ORIMED PHARMA October1 2026 escitalopram; October2026 sertraline randomized trial withdrawal

Remaining gaps: Read expanded mental-health scope and 20 named registries. New-study first 100 of 542 matches screened; broad query contains incidental symptom terms and later pages remain unretrieved. Selected post-trauma estradiol human entrant and Canadian liquid escitalopram access update; WELTRUZA approval not duplicated.; Canadian market-date/cache discrepancy not silently resolved. Earlier DISCARD protocol narrative says enrollment began February 18 while registry is stale, but full original protocol publication was inaccessible this pass; keep source conflict/access gap. All anxiety/OCD/PTSD/bipolar/addiction pipeline, long-term SSRI harms and guideline/label updates remain incomplete.

Informal sources and unresolved claims: Original/indexed Oct 11–12 liquid-escitalopram posts led to sponsor/Health Canada sources. Their first-North-America claim is contradicted by an older U.S. DailyMed label; no tapering-benefit claim adopted. Wider withdrawal anecdotes and informal drug-timing claims did not establish a selected new rumor; full podcast sweep incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23
• Source 24
• Source 25
• Source 26
• Source 27
• Source 28
• Source 29

Bone health, joint preservation and cartilage repair

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: osteoporosis OR cartilage repair OR lorecivivint OR TG-C; new human bone/cartilage/fracture trial results; abaloparatide denosumab primary completion; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 99 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved.

Informal sources and unresolved claims: Targeted original Reddit/new cartilage and osteoporosis program searches yielded no distinctive attributable development claim selected; full conference/podcast recordings remain unreviewed. This limited search is not absence of rumors.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16

Liver health and noninvasive assessment

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-13: liver primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: liver original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 138 records across 2 pages; incidental studies excluded. Named topic records refreshed: 12. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; EMA current Wegovy overview and available minutes still do not resolve the September MASH variation. September minutes expected after the October CHMP; no rejection/delay inferred from omission. Secondary CTIS mirror NEBULA authorization not independently established from primary EMA; record discrepancy retained. Worldwide fibrosis/noninvasive utility and complete FGF21 harms corpus remain incomplete.

Informal sources and unresolved claims: Revisited saved September 18 Reddit inference about Wegovy CHMP omission against current EMA page and available agendas/minutes. Outcome remains unconfirmed; no repeat alert. Searched MASH informal development claims without selecting a new attributable original signal; full audio remains incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21

Cancer treatment, vaccines and recurrence prevention

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: October2026 cancer trial October12 phase3results; site:fda.gov oncology October2026 approvals; October2026 REGAL 80 Sellas

Remaining gaps: Read expanded oncology topic/state and September 5 overlap; retrieved 26 saved registries and 65 new-study matches. Appraised selected new phase 3 HER2 ADC and phase 2a CAIX radiopharmaceutical registrations; no duplicate NRG-BR002 or prior vaccine/regulatory events.; FDA oncology index retrieved but its latest visible update remains September; not a comprehensive Oct 13 approval/label audit. BNT122 registry active/not-recruiting versus August 28 sponsor termination/futility/OS imbalance remains a source conflict; no restart inferred. NRG-BR002 full paper/toxicity and global cellular/radiopharmaceutical census remain incomplete.

Informal sources and unresolved claims: REGAL event 80 imminent inference rechecked against sponsor news index and new Reddit discussions; no official trigger or topline confirmation retrieved, index lacks rendered dynamic entries. Leave unconfirmed without repeat alert. Leronlimab/AlphaDaRT investor forecasts not efficacy/approval evidence. All original investor calls/transcripts remain incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23
• Source 24
• Source 25
• Source 26
• Source 27
• Source 28
• Source 29
• Source 30
• Source 31
• Source 32

Autoimmune disease and immune reset

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: CAR T OR immune reset OR fenebrutinib OR Treg with lupus/myositis/MS/RA; rap-cel/zola-cel restart; FB102 full result tables; Mount Sinai IBD CAR-T initiation; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 29 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved. C-CAR168 lupus record remains not yet recruiting after elapsed start; no verified rap-cel/zola-cel restart, full FB102 effect/harms or Mount Sinai IBD initiation.

Informal sources and unresolved claims: Revisited original lupus Reddit thread, which repeats prula-cel release and anonymous cross-trial safety predictions. These are not proof of safer platforms. Mehandru IBD planning remains unconfirmed without matched initiation; review literature is not confirmation of the specific Mount Sinai plan.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15

Non-opioid pain treatments

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: suzetrigine OR VX-993 OR onzotrigine OR LTG321 OR non-opioid; non-opioid human trials, current named protocols, chronic pain safety; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 52 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved. October13 TKA protocol update does not establish a new result; no new SL1002/VX993 numerical results recovered.

Informal sources and unresolved claims: Targeted pain Reddit searches surfaced old suzetrigine treatment experiences and review reposts; no distinct new program signal selected. Experiences do not establish chronic pain efficacy; full clinician podcasts remain unreviewed.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14

Kidney preservation and earlier detection

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: 2026-10-13: kidney primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: kidney original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 378 records across 4 pages; incidental studies excluded. Named topic records refreshed: 15. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; Existing finerenone non-diabetic CKD filing, PYC-003 ASN target-engagement and combination studies deduplicated. Farabursen full Phase 3 identifier still not resolved beyond Tufts CCYX082A12301 listing. ASN October 22 exact PYC protocol remains saved; no new kidney-volume numerical values inferred. Broader tissue-preservation, earlier-detection and full worldwide safety census incomplete.

Informal sources and unresolved claims: Revisited original ADPKD farabursen recruitment thread and matching investigator lead; no verified new outcome/global dosing date beyond saved Tufts listing. Targeted kidney/finerenone informal searches yielded no separate attributable milestone selected. Full podcast/audio and complete source-chain checks remain gaps.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21

Hearing and vision preservation/restoration

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: BRUNELLO remigromig October10 2026 AAO safety retinal adverse events results; MCO010 REMAIN four year October11 2026 AAO results; AC102 October2026 results hearing

Remaining gaps: Read topic/state and September 5 overlap; all 14 named registries and first 100 of 491 new-study matches retrieved. BRUNELLO primary October 10 detailed results appraised; direct Oct 11 MCO010 investigator interview/report confirms delivery and gives selected week 204 values.; MCO010 original slides, four-year denominators/CI/attrition and dryAMD PO624 exact tables remain unappraised; no inherited-RP/acquired-AMD substitution. BEST1 original PDF access and comprehensive common acquired-hearing inventory remain gaps. Remaining new-study pages not retrieved; many broad vision/hearing matches incidental.; Historical PRIMA/4 D150 data not repeated as fresh news. AC102 record remains January 16 snapshot with elapsed estimated completions and no posted result.

Informal sources and unresolved claims: Original BRUNELLO and MCO010 investigator interview reports appraised as conference/interview evidence, not peer-reviewed full tables. Existing anonymous AC102 sponsor-email/2027 plans remain unconfirmed after current registry and official tinnitus page check; no phase 3 start or chronic-tinnitus efficacy inferred. Full interview/podcast census incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23

Hair loss, restoration and graying

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: Named ClinicalTrials.gov API refresh and all pages of hair_loss discovery, LastUpdatePostDate September 5 to October 13, 2026; Primary sponsor/regulator/publisher and conference searches for hair_loss; October 9 to 13 prioritized, older within-window entries deduplicated; Original Reddit and selected podcast/transcript queries for hair_loss; unresolved earlier claims revisited; Europe PMC broad FirstPublicationDate September 5 to October 13 query; bounded title/abstract MED retry for hair, skin, scars, dental

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (97 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; Closed adult BRAVE-AA1/AA2 long-term paper gap and recovered RLS-1496 announced AGA trial as a new-to-watch program. AWAKEN, HEADLINE, VDPHL01, GT20029 and biological hair-graying records refreshed without new result/status alerts. Veradermics current investor news page failed; complete Kintor September 29 primary report, every international regulator/label and rare-harm census remain unappraised.

Informal sources and unresolved claims: Revisited original ToastedCaffeine BQ002 post and BioQ: candidate exists but 2027 start and candidate-specific human protocol remain unconfirmed; RLS keyword registry only returns AK, BQ002 query returns none. Cosmo July 23 still forecasts Q1 2027 U.S. filing; late 2027/2028 launch inference remains unconfirmed. PP405 community updates repeat saved recruitment. September 21 Citeline CEO episode description corroborates that RLS hair development was discussed, not patient regrowth; original audio unreviewed and secondary transcript direct fetch failed. No repeat rumor alert.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20
• Source 21
• Source 22
• Source 23
• Source 24
• Source 25
• Source 26
• Source 27
• Source 28
• Source 29
• Source 30
• Source 31

Skin aging, laxity and regeneration

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Named ClinicalTrials.gov API refresh and all pages of skin_aging discovery, LastUpdatePostDate September 5 to October 13, 2026; Primary sponsor/regulator/publisher and conference searches for skin_aging; October 9 to 13 prioritized, older within-window entries deduplicated; Original Reddit and selected podcast/transcript queries for skin_aging; unresolved earlier claims revisited; Europe PMC broad FirstPublicationDate September 5 to October 13 query; bounded title/abstract MED retry for hair, skin, scars, dental

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (70 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; New HU-045 glabellar-line Phase 3 registry appraised. KB304 remains active/not recruiting with stale 2025 estimate; ellacor nine-person cohort remains completed/no results. Existing post-weight-loss and secretome/energy-device claims deduplicated. RLS-1496 hair plan belongs to hair_loss; October 12 AK investigator interview is newly posted secondary context, not verified wrinkle rejuvenation. Original EADV228 abstract, full photoaging numerical tables, device clearance/rare-harm census remain gaps.

Informal sources and unresolved claims: September 22 Hot Water episode with Christie Prendergast found in original Apple listing and secondary Podcast Rex description; secondary summary attributes a clinic secretome trial plan but full transcript fetch failed, original audio/time passage unverified and possible overlap with saved Acorn program unresolved. Kept as follow-up lead, not newly verified trial or quoted statement. October 12 RLS posts frame senescence changes as age reversal; this interpretation is not proven clinical rejuvenation. Full originals remain gaps.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18

Scar prevention, treatment and stretch marks

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: Named ClinicalTrials.gov API refresh and all pages of scars discovery, LastUpdatePostDate September 5 to October 13, 2026; Primary sponsor/regulator/publisher and conference searches for scars; October 9 to 13 prioritized, older within-window entries deduplicated; Original Reddit and selected podcast/transcript queries for scars; unresolved earlier claims revisited; Europe PMC broad FirstPublicationDate September 5 to October 13 query; bounded title/abstract MED retry for hair, skin, scars, dental

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (224 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; SCARFREE remains not yet recruiting with October 2026/August–November 2028 estimates; no initiation presumed. Geneva verteporfin and siSPARC remain stale. Syntara October 1 expansion, silicone-tape and botulinum/laser reports already saved. New October 9 retrospective exosome acne-scar record has no posted outcomes; surgical-closure record October 9 update adds no verified efficacy. Full October 3 CO2-vs-microplasma paper, stretch-mark and rare-complication census remain unappraised.

Informal sources and unresolved claims: Targeted original Reddit/formal-program and Syntara searches did not recover a distinct attributable fresh milestone rumor. Off-label verteporfin self-experiments not converted to formal trial outcomes. Podcast and investor audio incomplete; no claim of absence.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16

Facial volume restoration and contour

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: Named ClinicalTrials.gov API refresh and all pages of facial_volume discovery, LastUpdatePostDate September 5 to October 13, 2026; Primary sponsor/regulator/publisher and conference searches for facial_volume; October 9 to 13 prioritized, older within-window entries deduplicated; Original Reddit and selected podcast/transcript queries for facial_volume; unresolved earlier claims revisited; Europe PMC broad FirstPublicationDate September 5 to October 13 query; bounded title/abstract MED retry for hair, skin, scars, dental

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (91 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; Merz September 14 original source still describes October 14 Volume and December 1 Intense availability as anticipated; tomorrow is a forecast, not current local inventory. Earlier exact approvals/formulations/age/anatomy remain separate. HArmonyCa completed/no results; macrofat and GLP1-Radiesse retain recruitment, Facetem/Radiesse comparisons retain plans. Full new-filler regulator/label inventory, pivotal harms, post-weight-loss comparisons and delayed complications remain gaps.

Informal sources and unresolved claims: October 9 graft-survival Reddit discussion concerns individual procedures and alternatives, not controlled outcome rates. Recent aesthetics workshop/podcast descriptions do not establish new product efficacy or launch. Full audio and original-source-chain census incomplete; no new rumor selected.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11

Pigmentation and uneven skin tone

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Named ClinicalTrials.gov API refresh and all pages of pigmentation discovery, LastUpdatePostDate September 5 to October 13, 2026; Primary sponsor/regulator/publisher and conference searches for pigmentation; October 9 to 13 prioritized, older within-window entries deduplicated; Original Reddit and selected podcast/transcript queries for pigmentation; unresolved earlier claims revisited; Europe PMC broad FirstPublicationDate September 5 to October 13 query; bounded title/abstract MED retry for hair, skin, scars, dental

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (54 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; New October 13 posted randomized toner/hydroquinone-adjunct results appraised with numerical lack of clear separation, unspecified formulation and no formal comparison statistics. STOP-V1/V2, China povorcitinib, DelVito and FXS5626 remain as saved; no new outcomes/approval asserted. Actual EADV P2467/P1780/P2463 posters, full worldwide melasma/PIH/solar-lentigine inventory, KT939 protocol/status remain gaps.

Informal sources and unresolved claims: Targeted October 9–13 Reddit vitiligo/melasma and talk searches did not recover a noteworthy attributable new trial forecast. Existing anonymous long-term povorcitinib anecdote does not verify blinded efficacy or approval; no duplicate alert. Full audio and informal-source census incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14

Acne and rosacea

Coverage: focused_incomplete. 0 newly recorded entries.

Searches: Named ClinicalTrials.gov API refresh and all pages of acne_rosacea discovery, LastUpdatePostDate September 5 to October 13, 2026; Primary sponsor/regulator/publisher and conference searches for acne_rosacea; October 9 to 13 prioritized, older within-window entries deduplicated; Original Reddit and selected podcast/transcript queries for acne_rosacea; unresolved earlier claims revisited; Europe PMC broad FirstPublicationDate September 5 to October 13 query; bounded title/abstract MED retry for hair, skin, scars, dental

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (53 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; AURORA recruiting 800 and B244 not-yet-recruiting 176 remain unchanged; October 9 site-activation announcement and September 30 Chinese denifanstat extension deduplicated. SP0268 vaccine and remibrutinib named records refreshed without new outcomes. October 11 interview reprises extension rather than a new trial event. Rosacea vessel/flushing/ocular, antibiotic resistance, U.S. label/device and complete safety census remain gaps.

Informal sources and unresolved claims: October 7 original London/Markham rosacea-recruitment Reddit post gives no uniquely verified drug identity; saved remibrutinib study remains recruiting separately. Targeted denifanstat/B244/new trial rumor queries found no distinct selected claim. Full sponsor KOL/Q&A replay and podcasts remain gaps.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17

Dental alignment, regeneration and repair

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: Named ClinicalTrials.gov API refresh and all pages of dental discovery, LastUpdatePostDate September 5 to October 13, 2026; Primary sponsor/regulator/publisher and conference searches for dental; October 9 to 13 prioritized, older within-window entries deduplicated; Original Reddit and selected podcast/transcript queries for dental; unresolved earlier claims revisited; Europe PMC broad FirstPublicationDate September 5 to October 13 query; bounded title/abstract MED retry for hair, skin, scars, dental

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (134 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; Recovered October 7 P11-4 full protocol and June 23 original record; primary endpoint and estimated finish mismatch retained. Toregem news ends October 6 BioJapan business announcement; actual PhaseIIa dosing and human tooth-regrowth efficacy unverified. Printed-aligner September 24 paper, OrthoPulse and stale NCT07496892 deduplicated. October 9 power-arm/miniscrew/bone-mixture registrations disclose completed/planned trials without outcomes, not comparative efficacy. Complete Japanese jRCT PhaseIIa record, alignment/root/gum/retention and full repair/regeneration census remain gaps.

Informal sources and unresolved claims: October 9 intrestingtoknow repost and October 12 askdentists question repeat TRG035/2030 timelines and extrapolate to acquired tooth loss; sponsor business-news page does not verify first dosing or efficacy. Reposts are not independent confirmation. Full dental/orthodontic recordings and Japanese originals incomplete; no fresh rumor alert.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19

Allergy and airway disease

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: asthma OR COPD OR food allergy OR chronic sinusitis human phases2/3; food/environmental allergy, acute-COPD and sinus trial results/new programs; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 135 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved. No fuller acute-COPD absolute effect/CI/harms or verified VIASKIN FDA action date recovered; broad food/sinus coverage incomplete.

Informal sources and unresolved claims: Targeted rademikibart/VIASKIN/asthma Reddit and podcast searches mainly returned known topline/submission reposts and patient experience. No fresh distinct development claim selected; full talk/transcript coverage incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15

Infectious-disease prevention and treatment

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: antibiotic OR bacteriophage OR vaccine OR antiviral human phases2/3; new antibiotics/phages/vaccine programs; Travelan primary paper and posted results; Targeted Reddit, podcast and informal new-program searches; saved unresolved-claim follow-up

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 325 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved.

Informal sources and unresolved claims: Targeted antibiotics/phage/vaccine Reddit and interview searches returned older studies and routine treatment anecdotes. No specific attributable new development rumor selected; full podcast/talk transcripts not appraised.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13
• Source 14
• Source 15
• Source 16
• Source 17
• Source 18
• Source 19
• Source 20

Genetic screening and risk prediction

Coverage: focused_incomplete. 3 newly recorded entries.

Searches: October2026 genomic screening trial study; October2026 embryo polygenic Nucleus trial; October2026 newborn genome study after:2026-10-08; October2026 pharmacogenomic trial results after:2026-10-08

Remaining gaps: Read broad genetics scope/state and September 6 overlap; all 7 saved registries plus 5 new registrations retrieved. Appraised full Oct 12 DPYD/UGT1 A1 toxicity and Oct 4 MLD newborn implementation papers; Oct 5 MECP2 pre-proof primary abstract retrieved but full article inaccessible.; PGTP NCT07841769 remains not-yet-recruiting in Sept 25 record despite elapsed Oct 1 estimate. MGB T1D genetic-risk study retains Oct 15 estimatedstart, not actual initiation. FOCUS Sept 8 record still has 8 enrollment versus 12 test-site narrative mismatch; not promoted to resolved baseline.; All PGT-M/SR/A guidance, carrier/cascade testing, multiancestry PRS intervention trials and newborn sequencing programs not comprehensively refreshed. MECP2 full infant outcomes and cancer-germline Oct 8 supplements remain gaps.

Informal sources and unresolved claims: Revisited original indexed Nucleus/Vitruvian source chain and matched live PGT-P registry: no clinical offspring-outcome confirmation or verified actual start; prior model 14.3 highest-to-lowest remains separate from top-versus-average gain. Newborn blog/case reports are not controlled outcomes. Full commercial/podcast transcript review incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13

Insomnia

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-13: sleep_insomnia primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: sleep_insomnia original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 136 records across 2 pages; incidental studies excluded. Named topic records refreshed: 5. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; New condition-specific baseline remains incomplete. Selected inherited older pivotal sources and newly recovered formal programs were reviewed, without declaring the preceding 90-day/older trial corpus complete.

Informal sources and unresolved claims: Original ENLIGHTEN-6 anonymous fragmented-sleep account is saved once in GLP-1 with cross-link; no incidence inference. Exact-date insomnia Reddit searches produced irrelevant pregnancy/old matches and no distinct formal-development rumor selected. Insomnia podcast/talk full recordings and broader informal safety census remain incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8

Obstructive sleep apnea

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: 2026-10-13: sleep_apnea primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: sleep_apnea original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 72 records across 1 pages; incidental studies excluded. Named topic records refreshed: 5. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; New condition-specific baseline remains incomplete. Selected inherited older pivotal sources and newly recovered formal programs were reviewed, without declaring the preceding 90-day/older trial corpus complete.

Informal sources and unresolved claims: Targeted original Reddit apnea drug/device discussions reviewed as leads, including prior AD109 launch speculation; sponsor CHEST announcement supplies a scheduled event only. No distinct new original unconfirmed development signal selected; device access and full podcast recordings incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8

Narcolepsy & excessive sleepiness

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-13: sleep_hypersomnolence primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: sleep_hypersomnolence original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 15 records across 1 pages; incidental studies excluded. Named topic records refreshed: 7. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; New condition-specific baseline remains incomplete. Selected inherited older pivotal sources and newly recovered formal programs were reviewed, without declaring the preceding 90-day/older trial corpus complete.

Informal sources and unresolved claims: Revisited original narcolepsy threads on expected Orzeyful availability and trial experiences; November forecast remains conditional and no official DEA action found. The older August 24 alixorexton paper is not new October news. No new verified availability or attributable development rumor selected; full talk/audio incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11
• Source 12
• Source 13

Circadian rhythm disorders

Coverage: focused_incomplete. 2 newly recorded entries.

Searches: 2026-10-13: sleep_circadian primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: sleep_circadian original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 161 records across 2 pages; incidental studies excluded. Named topic records refreshed: 3. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; New condition-specific baseline remains incomplete. Selected inherited older pivotal sources and newly recovered formal programs were reviewed, without declaring the preceding 90-day/older trial corpus complete.

Informal sources and unresolved claims: Targeted original DSPD, Non-24 and shift-work informal searches did not yield a distinct sourced development signal selected for inclusion. Some exact-date searches failed to return relevant posts. Full talks/audio, the jet-lag hearing outcome and disorder-specific patient-experience coverage remain incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7

Restless legs syndrome

Coverage: focused_incomplete. 1 newly recorded entries.

Searches: 2026-10-13: sleep_restless_legs primary trial, registry, sponsor/regulator and new human-program searches; September 5–October 13 overlap; 2026-10-13: sleep_restless_legs original Reddit/informal development searches and saved rumor follow-up

Remaining gaps: Read current canonical scope, shared summaries/state and assigned topic notes. September 5–October 13 overlap preserves the September 12 full-review dates; October 6/9 entries were deduplicated. All pages of each bounded ClinicalTrials.gov query were downloaded, and named records plus selected relevant new/changed protocols were appraised. This is focused partial review, not a worldwide full literature/regulator/safety census; successful full-topic dates must remain unchanged.; Bounded query retrieved 7 records across 1 pages; incidental studies excluded. Named topic records refreshed: 6. Full older evidence, international registries, comprehensive harms and all original conference/podcast recordings remain gaps.; New condition-specific baseline remains incomplete. Selected inherited older pivotal sources and newly recovered formal programs were reviewed, without declaring the preceding 90-day/older trial corpus complete.

Informal sources and unresolved claims: Reviewed the original October 7 RLS-algorithm discussion and October 9 patient thread. Drug, stevia and device experiences are not formal new trial results. A TOMAC meta-analysis/corrigendum appears in an October issue, but the original publication date and full correction remain unappraised; the issue date is not treated as new research. No distinct new development rumor was selected. Full SOS/SLEEP presentations and audio remain incomplete.

Sources checked:

• Source 1
• Source 2
• Source 3
• Source 4
• Source 5
• Source 6
• Source 7
• Source 8
• Source 9
• Source 10
• Source 11

Homepage and publication

The October 3 EloraTZP feature remains useful after ten days, with matched efficacy and harms. New vision results add important safety tradeoffs in the relevant topic. The feature will be reconsidered with the next substantive release; no invented chart values or simulated trial trajectories are added. Historical numerical plots retain their original data, populations and intervals. Public export excludes personal notes and identifying context. This background run uses release validators and native deployment status; no browser QA is claimed. Publication receipt is recorded in state only after success.